Cargando…
Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
PURPOSE: The Coronavirus disease 2019 (COVID-19) pandemic is one of the most devastating global problems. Regarding the lack of disease-specific treatments, repurposing drug therapy is currently considered a promising therapeutic approach in pandemic situations. Recently, the combination therapy of...
Autores principales: | Akbarzadeh-Khiavi, Mostafa, Torabi, Mitra, Rahbarnia, Leila, Safary, Azam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666469/ https://www.ncbi.nlm.nih.gov/pubmed/34902115 http://dx.doi.org/10.1007/s15010-021-01730-6 |
Ejemplares similares
-
SARS-CoV-2 vaccine-triggered autoimmunity: Molecular mimicry and/or bystander activation of the immune system
por: Safary, Azam, et al.
Publicado: (2023) -
Correction to: Micronutrient therapy and effective immune response: a promising approach for management of COVID-19
por: Lotfi, Fariba, et al.
Publicado: (2022) -
Micronutrient therapy and effective immune response: a promising approach for management of COVID-19
por: Lotfi, Fariba, et al.
Publicado: (2021) -
Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates
por: Akbarzadeh Khiavi, Mostafa, et al.
Publicado: (2019) -
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
por: Praveen, D., et al.
Publicado: (2020)